Novel Benzimidazole‐Pyridine‐Phenylalkanesulfonate Hybrids: Design, Synthesis, Antimicrobial Screening, Lanosterol 14α‐Demethylase Inhibition Properties and in Silico Studies
Drug Development Research · 2025-08 · 86 (5)
DOI: 10.1002/ddr.70122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 23.06.2025. Verfasst von Aisha A K Al-Ashmawy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Therapeutic Chemistry, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Dokki, Cairo, Egypt. Hauptthemen laut MEDLINE: Pyridines, Benzimidazoles, 14-alpha Demethylase Inhibitors, Sterol 14-Demethylase. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
A newly designed benzimidazole‐pyridine‐pheylalkanesulfonate hybrids ( 3a‐r ) were synthesized through the regioselective Michael addition reaction between 2‐acetyl‐1‐substituted‐benzimidazole ( 1 ) and dicyano vinyl alkanesulfonate ( 2 ) to evaluate their activity against diverse microbial pathogens including Candida albicans (a unicellular fungus), Bacillus subtilis and Staphylococcus aureus (Gram‐positive bacteria), as well as Pseudomonas aeruginosa , Klebsiella pneumoniae , and Salmonella typhimurium (Gram‐negative bacteria). Although most of the tested hybrids showed promising antimicrobial potentiality, the MIC was calculated for the two precursors 1a , b in addition to derivatives 3b , 3 g , 3k , 3 m and 3p that found to prevent the proliferation of all microbial pathogens with different ratios in comparison to the reference drug used. Compound 3k demonstrated the best anti‐candida properties with MIC = 5 μ g/mL (amphotericin B, MIC = 20 μ g/mL), and it was of equal efficacy to ciprofloxacin against Staphylococcus aureus with MIC = 20 μ g/mL. Derivatives 3b and 3 m displayed equipotent activity to ciprofloxacin with MICs = 10 μ g/mL against S. typhimurium and B. subtilis , respectively. Moreover, derivative 3 m exhibited 42.1% biofilm inhibition against P. aeruginosa (compared with 39.8% for Ciprofloxacin). An acceptable safety profile of the most potent derivatives was detected. The impact of the 3b and 3k hybrids on the tested microbial pathogens was visualized using CLSM. Furthermore, 3k inhibited the Lanosterol 14α‐demethylase (CYP51) with IC 50 = 4.2 μ M (fluconazole IC 50 = 0.6 μ M). Furthermore, in silico studies including ADME prediction for the five promising hits and molecular docking simulation of 3k in the demethylase binding site were performed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Therapeutic Chemistry, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Dokki, Cairo, Egypt.
- Microbial Chemistry Department, Biotechnology Research Institute, National Research Centre Dokki, Cairo, Egypt.
- Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
ORCID-Profile: Aisha A K Al-Ashmawy, Asmaa Saleh, Aladdin M Srour
Zitieren
APA
Al-Ashmawy, A. A. K., Abdelraof, M., Saleh, A., & Srour, A. M. (2025). Novel Benzimidazole‐Pyridine‐Phenylalkanesulfonate Hybrids: Design, Synthesis, Antimicrobial Screening, Lanosterol 14α‐Demethylase Inhibition Properties and in Silico Studies. Drug Development Research, 86(5). https://doi.org/10.1002/ddr.70122
Vancouver
Al-Ashmawy AAK, Abdelraof M, Saleh A, Srour AM. Novel Benzimidazole‐Pyridine‐Phenylalkanesulfonate Hybrids: Design, Synthesis, Antimicrobial Screening, Lanosterol 14α‐Demethylase Inhibition Properties and in Silico Studies. Drug Development Research. 2025;86(5). doi:10.1002/ddr.70122
BibTeX
@article{AlAshmawy2025,
author = {Al-Ashmawy, Aisha A K and Abdelraof, Mohamed and Saleh, Asmaa and Srour, Aladdin M},
title = {Novel Benzimidazole‐Pyridine‐Phenylalkanesulfonate Hybrids: Design, Synthesis, Antimicrobial Screening, Lanosterol 14α‐Demethylase Inhibition Properties and in Silico Studies},
journal = {Drug Development Research},
year = {2025},
volume = {86},
number = {5},
doi = {10.1002/ddr.70122}
}
EUVIMED